E2G (p.Glu2Gly) variant of TP53 (Cellular tumor antigen p53)
E2G (p.Glu2Gly) in TP53 (Cellular tumor antigen p53) is a missense change. Clinical records from ClinVar, EBI, and UniProt describe it as uncertain significance in the context of Li-Fraumeni syndrome 1; Hereditary cancer-predisposing syndrome; Li-Fraumeni syn. The available variant effect predictions contribute to a CATVariant prioritization score of 0.55 / 1. The record also includes experimental measurements, published literature, and structural context.
E2G (p.Glu2Gly) variant details
- p.Glu2Gly
- rs2073524631
- ClinGen CA397849519
- ClinVar RCV001189589
- ClinVar RCV001876218
- Uncertain significance
- Li-Fraumeni syndrome 1; Hereditary cancer-predisposing syndrome; Li-Fraumeni syn
- Missense
- Variant Prioritization Score for Impact Estimate 0.545
- ESM-1b 0.00
- AlphaMissense 0.19
- MetaLR 0.96
- MetaSVM 1.02
- PolyPhen-2 0.96
- SIFT 0.00
- ClinVar: Uncertain significance (Li-Fraumeni syndrome 1; Hereditary cancer-predisposing syndrome;)
- EBI: Variant of uncertain significance
- UniProt: Uncertain significance
- Structural context available
- p53 variant effect measured by cell growth: score -2.68
- Cited in: A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic… (PMID 25394175)
- Cited in: American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. (PMID 17392385)